Merck obtains rights to Teijin's tau candidate

Teijin Pharma Ltd. (Tokyo, Japan) granted Merck & Co. Inc. (NYSE:MRK) exclusive rights to an undisclosed preclinical antibody targeting microtubule-associated protein tau (tau; MAPT; FTDP-17). Merck plans

Read the full 278 word article

How to gain access

Continue reading with a
two-week free trial.